Advertisement
U.S. markets closed

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4700-0.0500 (-3.29%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.5200
Open1.4800
Bid1.4000 x 900
Ask1.5600 x 800
Day's Range1.4400 - 1.5457
52 Week Range0.9800 - 1.9200
Volume299,799
Avg. Volume104,714
Market Cap41.017M
Beta (5Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-2.3500
Earnings DateFeb 29, 2024 - Mar 04, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NXTC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NextCure, Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
    Rating
    Fair Value
    Economic Moat
    17 days agoMorningstar
View more